Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
SRZNthis companySurrozen, Inc.	$32.38	-0.7×	-0.9×	48.61×	-0.36×	-60.9%	84.6%	-1210.6%	-6960.8%	128.9%	-46.7%	-18.0%	-0.04×	0.34×	0×	9.22×	0.0%	1	-15.27	2	C+
AGENAgenus Inc.	$7.55	-923.53×	-0.34×	0.82×	6.84×	-468.1%	29.6%	-18.0%	0.1%	-0.0%	-34.5%	-170.2%	-1.24×	5.34×	-0.37×	0.41×	0.0%	6	-14.32	2	C+
ATOSAtossa Therapeutics, Inc.	$2.14	-2.19×	1.94×	0×	-1×	88.9%	0.0%	0.0%	0.0%	-88.4%	-94.4%	-39.1%	0×	1.19×	0×	5.53×	0.0%	1	-11.86	2	B-
CGTXCognition Therapeutics, Inc.	$0.69	-4.22×	2.87×	0×	-2.67×	-14.9%	0.0%	0.0%	0.0%	-68.5%	-136.9%	-25.0%	0.02×	1.56×	-3,676.85×	3.45×	0.0%	1	-0.97	2	C+
GLSIGreenwich LifeSciences, Inc.	$16.47	-14.69×	805.09×	0×	-14.37×	-99.2%	0.0%	0.0%	0.0%	-5480.5%	-5505.9%	-3.5%	0×	0.32×	0×	1.06×	0.0%	1	2.27	1	D+
IMMXImmix Biopharma, Inc.	$8.63	-5.88×	1.84×	0×	-2.69×	-63.4%	0.0%	0.0%	0.0%	-31.4%	-31.6%	-14.3%	0.01×	3.14×	0×	10.01×	0.0%	2	35.26	2	C+
Peer median	—	-5.88×	1.94×	0×	-2.67×	-63.4%	0.0%	0.0%	0.0%	-68.5%	-94.4%	-25.0%	0×	1.56×	0×	3.45×	0.0%	1	-0.97	2	—